FREE Summit
Tuesday, September 22, 2020
10:00 AM - 1:30 PM, Eastern Standard Time
In the field of immuno-oncology, adoptive cell therapy is widely recognized for its promise to elicit effective long-term anti-cancer immunity. Cancer immunotherapy harnesses the power of the immune system by adoptively transferring tumor-infiltrating lymphocytes or modified peripheral blood immune cells into cancer patients to mediate long lasting anti-tumor responses.
During this summit, leading scientists in the field of cancer immunotherapy will present their research and perspectives on:
- Mechanisms underlying T cell signaling and efficacy
- Characterization of cellular phenotype and function prior to T cell expansion
- Factors influencing T cell performance when treating aggressive and challenging cancers
Summit program
Biology and Efficacy of Synthetic Antigen Receptors that Signal via the TCR
Jonathan Bramson, PhD
Vice-Dean Research, Faculty of Health Sciences
Professor, Pathology and Molecular Medicine, McMaster University
Canada Research Chair in Translational Cancer Immunology
CSO, Triumvira Immunologics
Understanding Resistance to Develop Better CAR T Immunotherapies
Marco Ruella, MD
Assistant Professor of Medicine
Scientific Director Lymphoma Program
Center for Cellular Immunotherapies
University of Pennsylvania
Advancing CAR T Cells for Glioblastoma Treatment: Progress and Challenges
Christine E. Brown, PhD
Heritage Provider Network Professor in Immunotherapy
Deputy Director, T-cell Therapeutics Research Laboratory
Department of Hematology & Hematopoietic Cell Transplantation
City of Hope Comprehensive Cancer Center
High Content Functional and Phenotypic Flow Cytometric Analysis of TILs: Guidance for Therapy and Improvement of Product Development
Markus Maeurer, MD, PhD, FRCP (London)
Head of Immunotherapy/Immunosurgery Program
Champalimaud Foundation, Portugal
I Med Clinical, University of Mainz, Germany
Summit sponsored by
.jpg){kind=logo}
